SAR-260301

• CAT Number: I009286
• CAS Number: 1260612-13-2
• Molecular Formula: C19H22N4O3
• Molecular Weight: 354.40
• Purity: ≥95%
• Synonyms: 2-[2-[(2S)-2-methyl-2,3-dihydroindol-1-yl]-2-oxoethyl]-4-morpholin-4-yl-1H-pyrimidin-6-one
• InChI: InChI=1S/C19H22N4O3/c1-13-10-14-4-2-3-5-15(14)23(13)19(25)11-16-20-17(12-18(24)21-16)22-6-8-26-9-7-22/h2-5,12-13H,6-11H2,1H3,(H,20,21,24)/t13-/m0/s1
• InChIKey: UAXHPOBBKRWJGA-ZDUSSCGKSA-N
• SMILES: CC1CC2=CC=CC=C2N1C(=O)CC3=NC(=CC(=O)N3)N4CCOCC4

SAR-260301 (Cat No.: I009286) is a selective, small-molecule inhibitor of phosphoinositide 3-kinase beta (PI3Kβ), developed for cancer research. By targeting PI3Kβ, a key component of the PI3K/AKT signaling pathway, SAR-260301 disrupts cellular processes such as proliferation, survival, and migration—especially in tumors with PTEN loss or PI3K pathway activation. It is primarily studied in preclinical and early clinical settings for its potential in treating solid tumors and hematologic malignancies. SAR-260301 helps elucidate isoform-specific PI3K inhibition and guides targeted therapeutic strategies in oncology.

Reference

[1]. Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
[Content Brief]

[2]. Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
[Content Brief]